RT Journal Article
SR Electronic
T1 Genetic and non-genetic factors affecting the expression of COVID-19 relevant genes in the large airway epithelium
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.01.20202820
DO 10.1101/2020.10.01.20202820
A1 Silva Kasela
A1 Victor E Ortega
A1 Molly Martorella
A1 Suresh Garudadri
A1 Jenna Nguyen
A1 Elizabeth Ampleford
A1 Anu Pasanen
A1 Srilaxmi Nerella
A1 Kristina L Buschur
A1 Igor Z Barjaktarevic
A1 R Graham Barr
A1 Eugene R Bleecker
A1 Russell P Bowler
A1 Alejandro P Comellas
A1 Christopher B Cooper
A1 David J Couper
A1 Gerard J Criner
A1 Jeffrey L Curtis
A1 MeiLan K Han
A1 Nadia N Hansel
A1 Eric A Hoffman
A1 Robert J Kaner
A1 Jerry A Krishnan
A1 Fernando J Martinez
A1 Merry-Lynn N McDonald
A1 Deborah A Meyers
A1 Robert Paine, 3rd
A1 Stephen P Peters
A1 Mario Castro
A1 Loren C Denlinger
A1 Serpil C Erzurum
A1 John V Fahy
A1 Elliot Israel
A1 Nizar N Jarjour
A1 Bruce D Levy
A1 Xingnan Li
A1 Wendy C Moore
A1 Sally E Wenzel
A1 Joe Zein
A1 NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS)
A1 NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium
A1 Charles Langelier
A1 Prescott G Woodruff
A1 Tuuli Lappalainen
A1 Stephanie A Christenson
YR 2020
UL http://medrxiv.org/content/early/2020/10/04/2020.10.01.20202820.abstract
AB Particular host and environmental factors influence susceptibility to severe COVID-19. We analyzed RNA-sequencing data from bronchial epithelial brushings - a relevant tissue for SARS-CoV-2 infection - obtained from three cohorts of uninfected individuals, and investigated how non-genetic and genetic factors affect the regulation of host genes implicated in COVID-19. We found that ACE2 expression was higher in relation to active smoking, obesity, and hypertension that are known risk factors of COVID-19 severity, while an association with interferon-related inflammation was driven by the truncated, non-binding ACE2 isoform. We discovered that expression patterns of a suppressed airway immune response to early SARS-CoV-2 infection, compared to other viruses, are similar to patterns associated with obesity, hypertension, and cardiovascular disease, which may thus contribute to a COVID-19-susceptible airway environment. eQTL mapping identified regulatory variants for genes implicated in COVID-19, some of which had pheWAS evidence for their potential role in respiratory infections. These data provide evidence that clinically relevant variation in the expression of COVID-19-related genes is associated with host factors, environmental exposures, and likely host genetic variation.Competing Interest StatementS.A.C. advises for AstraZeneca, GlaxoSmithKline, Glenmark Pharmaceuticals, and Amgen, gave invited lectures to Sonovion and Genentech, and writes for UpToDate. T.L. advises and has equity in Variant Bio, and is a member of the scientific advisory board of Goldfinch Bio. V.E.O. has served and currently serves on Independent Data and Monitoring Committee for Regeneron and Sanofi for COVID-19 therapeutic clinical trials unrelated to the current manuscript.Funding StatementThis work was funded by following funding sources: R01HL142992 (V.E.O.), R01HL137880 (V.E.O.), F30HG011194 (M.M.), R01MH106842 (T.L.), R01HL142028 (T.L., R.G.B. and S.K.), R01GM122924 (T.L.), UM1HG008901 (T.L.), R01GM124486 (T.L.), K23HL123778 (S.A.C.), R01HL121774 (S.A.C.), U01HL137880 (S.A.C.). Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). Genome Sequencing for "NHLBI TOPMed: SubPopulations and InteRmediate Outcome Measures In COPD Study" (phs001927) was performed at the Broad Institute Genomics Platform (HHSN268201600034I). Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), grants from the NIH/NHLBI (U01 HL137880 and U24 HL141762), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; Novartis Pharmaceuticals Corporation; Nycomed GmbH; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Columbia University IRB 2 (AAAE9315), University of Iowa IRB-01 (201308719), Johns Hopkins IRB-5 (NA_00035701), UCLA Medical IRB 1 (MIRB1) (10001740/ 18-000403), University of Michigan IRBMED B1 Board (HUM00036346/ HUM00141222), National Jewish Health IRB (HS2678), UCSF IRB Parnassus Panel (10-03169), Temple University IRB A2 (21416), U of Alabama at Birmingham IRB #2 (120906004), University of Illinois IRB #3 (2013-0939), University of Utah IRB Panel Review Board 5 (00027298/ 00108836), Wake Forest University IRB #5 (00012805/ 00048727), UNC Non-Biomedical IRB (10-0048), UCLA Medical IRB 1 (MIRB1) (18-000458), University of Iowa IRB-01 (201003733).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe SPIROMICS gene expression data will be available in dbGaP. The SARP gene expression data will be available through the Gene Expression Omnibus (GEO). The MAST dataset is available in GEO under accession number GSE67472. TOPMed WGS freeze 9 data are available in dbGaP under accession number phs001927. Full eQTL summary statistics for the 496 COVID-19-related genes can be downloaded from https://github.com/LappalainenLab/spiromics-covid19-eqtl/tree/master/eqtl/summary_stats. https://github.com/LappalainenLab/spiromics-covid19-eqtl/tree/master/eqtl/summary_stats